Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Martin Pule

Tim Funnell

Autolus Therapeutics plc

SOTIO Biotech develops immunotherapies for cancer treatment, focusing on advancing safer and effective options through clinical development. The company self-describes as focusing on a broad pipeline addressing various solid tumor types.

SOTIO Biotech

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. 

Metric
Company Name	Autolus Therapeutics plc	SOTIO Biotech
Symbol	AUTL
MSH ID	COM:AUTOLUS	COM:SOTIO
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	GB	CZ
Stage		Venture Round
Employee Count	463
Website	autolus.com	sotio.com
LinkedIn	autolus-ltd-	sotio
Founders

Metric
Market Cap	1.05B
Enterprise Value
Monthly Web Traffic		3.94K
Web Traffic Growth		-0.39
Valuation
Raised Capital		316.57M

Metric
Revenue	1.70M
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.70M
EBITDA	-175.53M
Operating Income	-175.53M
Net Income	-208.38M
EPS	-1.20
Diluted EPS	-1.20
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.55
Operating Profit Margin	-14.00
EBITDA Margin	-103.37
Net Profit Margin	-18.03
Return on Equity	-0.67
Return on Assets	-0.25
Return on Capital Employed	-0.20

COM:AUTOLUS

Autolus Therapeutics plc

Last Close

2.84

22/11 21:00

Market Cap

609.42M

Beta: -

Volume Today

1.60M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-6.85
P/B Ratio	6.00
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	673.64
EV Multiple	-5.21

Metric
Days Sales Outstanding	2.77K
Days Payables Outstanding	631.58
Days Inventory Outstanding	950.75
Operating Cycle	9.97K
Cash Conversion Cycle	9.91K
Asset Turnover	0.01

Metric
Operating Cash Flow	-145.59M
Free Cash Flow	-145.59M
Cash Flow to Debt	-0.62
Operating Cash Flow/Sales	-11.71
Free Cash Flow Yield	-0.13

Metric
Cash & Equivalents	239.57M
Accounts Receivable
Inventory	-24.54M
Goodwill
Debt to Capitalization	0.32
Debt to Assets	0.13
Current Ratio	8.21
Quick Ratio	18.50

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	2.05
R&D to Revenue	24.90
SG&A to Revenue	6.96